Hearing loss and erythromycin pharmacokinetics in a patient receiving hemodialysis.
Arch Intern Med
; 143(6): 1263-5, 1983 Jun.
Article
en En
| MEDLINE
| ID: mdl-6860057
A left upper lobe pneumonia developed in a patient who was receiving hemodialysis; he was treated intravenously with 1 g of erythromycin lactobionate every six hours. After five doses, hearing loss was noted; this was later documented by audiogram. Erythromycin serum concentrations as high as 100 mg/L and a half-life more than three times longer than normal were observed. To our knowledge, this represents the first report of reversible hearing loss associated with elevated serum erythromycin concentrations and prolonged serum half-life.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Eritromicina
/
Diálisis Renal
/
Pérdida Auditiva Funcional
/
Pérdida Auditiva
Límite:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Arch Intern Med
Año:
1983
Tipo del documento:
Article
Pais de publicación:
Estados Unidos